| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
57,080,000 |
| Market
Cap: |
196.93(M) |
| Last
Volume: |
97,895 |
Avg
Vol: |
97,622 |
| 52
Week Range: |
$1.32 - $4.2 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.5 |
| Insider 6 Months : 5.2 |
| Insider 3/6 Months : 9.9 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Galectin Therapeutics is a clinical stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease, cancer and selected other diseases. Co.'s main galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. GR-MD-02 has the potential to treat various diseases due to galectin-3's involvement in multiple main biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
3,500 |
4,000 |
5,598 |
32,898 |
| Total Buy Value |
$10,840 |
$11,733 |
$14,587 |
$57,671 |
| Total People Bought |
2 |
3 |
3 |
5 |
| Total Buy Transactions |
2 |
3 |
4 |
11 |
| Total Shares Sold |
25,000 |
25,000 |
25,000 |
45,000 |
| Total Sell Value |
$76,500 |
$76,500 |
$76,500 |
$118,240 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
2 |
2 |
2 |
4 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Freeman Kevin D |
|
• • – |
2022-01-19 |
4 |
B |
$1.96 |
$9,806 |
I/I |
5,000 |
50,000 |
0.01 |
-34% |
|
| Freeman Kevin D |
|
• • – |
2022-01-19 |
4/A |
B |
$1.96 |
$9,806 |
I/I |
5,000 |
55,000 |
0.01 |
- |
|
| Zordani Richard A. Jr. |
|
• • – |
2022-01-14 |
4 |
B |
$2.02 |
$10,100 |
D/D |
5,000 |
19,583 |
0.01 |
-38% |
|
| Lewis Joel |
President and CEO |
• • – |
2022-01-14 |
4 |
A |
$2.02 |
$16,667 |
D/D |
8,251 |
307,868 |
|
- |
|
| Czirr James C |
Director |
– • • |
2022-01-11 |
4 |
AS |
$2.10 |
$21,000 |
D/D |
(10,000) |
6,188,940 |
|
-40% |
|
| Lewis Joel |
President and CEO |
• • – |
2021-12-31 |
4 |
A |
$2.07 |
$16,668 |
D/D |
8,052 |
299,617 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2021-12-15 |
4 |
A |
$2.25 |
$16,666 |
D/D |
7,407 |
291,565 |
|
- |
|
| Freeman Kevin D |
|
• • – |
2021-12-15 |
4/A |
B |
$2.28 |
$11,400 |
I/I |
5,000 |
50,000 |
0.01 |
- |
|
| Freeman Kevin D |
|
• • – |
2021-12-06 |
4 |
B |
$2.28 |
$11,400 |
I/I |
5,000 |
50,000 |
0.01 |
-29% |
|
| Freeman Kevin D |
|
• • – |
2021-12-06 |
4 |
B |
$2.34 |
$11,700 |
I/I |
5,000 |
45,000 |
0.01 |
-29% |
|
| Czirr James C |
Director |
– • • |
2021-12-02 |
4 |
AS |
$2.37 |
$23,700 |
D/D |
(10,000) |
6,198,940 |
|
-24% |
|
| Lewis Joel |
President and CEO |
• • – |
2021-11-15 |
4 |
A |
$2.86 |
$16,668 |
D/D |
5,828 |
277,821 |
|
- |
|
| Czirr James C |
Director |
– • • |
2021-11-01 |
4 |
AS |
$3.19 |
$31,900 |
D/D |
(10,000) |
6,208,940 |
|
-47% |
|
| Freeman Kevin D |
|
• • – |
2021-10-21 |
4 |
B |
$3.19 |
$6,380 |
I/I |
2,000 |
38,000 |
0.01 |
-44% |
|
| Freeman Kevin D |
|
• • – |
2021-10-19 |
4 |
B |
$3.37 |
$10,107 |
I/I |
3,000 |
36,000 |
0.01 |
-45% |
|
| Czirr James C |
Director |
– • • |
2021-10-15 |
4 |
S |
$3.37 |
$33,700 |
D/D |
(10,000) |
6,218,940 |
|
45% |
|
| Lewis Joel |
President and CEO |
• • – |
2021-10-15 |
4 |
A |
$3.37 |
$16,668 |
D/D |
4,946 |
266,735 |
|
- |
|
| Czirr James C |
Director |
– • • |
2021-10-04 |
4 |
AS |
$3.62 |
$36,200 |
D/D |
(10,000) |
6,228,940 |
|
-46% |
|
| Lewis Joel |
President and CEO |
• • – |
2021-09-30 |
4 |
A |
$3.88 |
$16,668 |
D/D |
4,296 |
261,789 |
|
- |
|
| Freeman Kevin D |
|
• • – |
2021-09-23 |
4 |
B |
$3.88 |
$11,631 |
I/I |
3,000 |
33,000 |
0.01 |
-48% |
|
| Lewis Joel |
President and CEO |
• • – |
2021-09-15 |
4 |
A |
$3.73 |
$16,666 |
D/D |
4,468 |
257,493 |
|
- |
|
| Czirr James C |
Director |
– • • |
2021-09-01 |
4 |
AS |
$3.91 |
$39,100 |
D/D |
(10,000) |
6,238,940 |
|
-46% |
|
| Lewis Joel |
President and CEO |
• • – |
2021-08-31 |
4 |
A |
$3.93 |
$16,667 |
D/D |
4,241 |
253,025 |
|
- |
|
| Lewis Joel |
President and CEO |
• • – |
2021-08-13 |
4 |
A |
$3.38 |
$16,667 |
D/D |
4,931 |
248,784 |
|
- |
|
| 10x Capital Management, Llc |
10% Owner |
– – • |
2021-08-02 |
4 |
AS |
$3.25 |
$32,500 |
D/D |
(10,000) |
6,248,940 |
|
-27% |
|
516 Records found
|
|
Page 4 of 21 |
|
|
0.05 (1.43%) 
